| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscle, Smooth, Vascular | 69 | 2022 | 1488 | 8.990 |
Why?
|
| Vasoconstriction | 52 | 2022 | 592 | 8.020 |
Why?
|
| Matrix Metalloproteinases | 18 | 2021 | 392 | 6.720 |
Why?
|
| Vasodilation | 38 | 2021 | 966 | 6.610 |
Why?
|
| Uterus | 17 | 2024 | 650 | 4.130 |
Why?
|
| Matrix Metalloproteinase 2 | 13 | 2022 | 459 | 3.970 |
Why?
|
| Endothelium, Vascular | 37 | 2019 | 4421 | 3.930 |
Why?
|
| Matrix Metalloproteinase 9 | 12 | 2024 | 631 | 3.710 |
Why?
|
| Pre-Eclampsia | 19 | 2022 | 1231 | 3.650 |
Why?
|
| Hypertension, Pregnancy-Induced | 10 | 2024 | 518 | 3.560 |
Why?
|
| Placenta | 20 | 2024 | 1709 | 3.470 |
Why?
|
| Varicose Veins | 13 | 2020 | 156 | 3.430 |
Why?
|
| Vascular Diseases | 11 | 2022 | 1160 | 3.070 |
Why?
|
| Nitric Oxide | 31 | 2021 | 2135 | 3.020 |
Why?
|
| Hypertension | 38 | 2023 | 8537 | 2.980 |
Why?
|
| Uterine Artery | 4 | 2024 | 30 | 2.880 |
Why?
|
| Muscle Contraction | 26 | 2021 | 1200 | 2.760 |
Why?
|
| Vena Cava, Inferior | 11 | 2020 | 459 | 2.700 |
Why?
|
| Rats, Sprague-Dawley | 57 | 2024 | 8164 | 2.580 |
Why?
|
| Vasoconstrictor Agents | 30 | 2023 | 654 | 2.520 |
Why?
|
| Pregnancy, Animal | 11 | 2014 | 124 | 2.470 |
Why?
|
| Protein Kinase C | 24 | 2016 | 1202 | 2.440 |
Why?
|
| ADAM Proteins | 5 | 2022 | 238 | 2.380 |
Why?
|
| Calcium | 40 | 2016 | 5720 | 2.280 |
Why?
|
| Phenylephrine | 33 | 2016 | 293 | 2.050 |
Why?
|
| Cyclic GMP | 15 | 2017 | 395 | 2.020 |
Why?
|
| Estrogens | 13 | 2023 | 1521 | 1.980 |
Why?
|
| Pregnancy Complications, Cardiovascular | 11 | 2016 | 513 | 1.950 |
Why?
|
| Ischemia | 12 | 2024 | 1889 | 1.930 |
Why?
|
| Uterine Contraction | 4 | 2022 | 91 | 1.880 |
Why?
|
| Rats | 64 | 2024 | 23713 | 1.810 |
Why?
|
| Calcium Signaling | 11 | 2018 | 732 | 1.800 |
Why?
|
| Receptor, Endothelin B | 5 | 2014 | 45 | 1.800 |
Why?
|
| Blood Pressure | 32 | 2024 | 8478 | 1.670 |
Why?
|
| Disintegrins | 3 | 2022 | 27 | 1.660 |
Why?
|
| Biological Factors | 3 | 2023 | 158 | 1.640 |
Why?
|
| Progesterone | 10 | 2022 | 742 | 1.620 |
Why?
|
| Hypertension, Pulmonary | 6 | 2022 | 1585 | 1.480 |
Why?
|
| Receptors, Estrogen | 11 | 2013 | 2208 | 1.460 |
Why?
|
| Estrogen Receptor beta | 5 | 2015 | 168 | 1.440 |
Why?
|
| Blood Vessels | 9 | 2017 | 1111 | 1.420 |
Why?
|
| Caveolin 1 | 4 | 2015 | 255 | 1.400 |
Why?
|
| Aorta | 21 | 2017 | 2040 | 1.390 |
Why?
|
| Estrogen Replacement Therapy | 6 | 2013 | 1208 | 1.370 |
Why?
|
| Gonadal Steroid Hormones | 8 | 2010 | 702 | 1.370 |
Why?
|
| Pregnancy | 56 | 2024 | 29872 | 1.360 |
Why?
|
| Neovascularization, Physiologic | 5 | 2021 | 1347 | 1.310 |
Why?
|
| Animals | 140 | 2024 | 168083 | 1.310 |
Why?
|
| Glycosaminoglycans | 3 | 2024 | 607 | 1.270 |
Why?
|
| Mesenteric Arteries | 5 | 2021 | 178 | 1.270 |
Why?
|
| Angiotensin II | 10 | 2023 | 848 | 1.170 |
Why?
|
| Microvessels | 4 | 2022 | 580 | 1.160 |
Why?
|
| Estrogen Receptor alpha | 5 | 2015 | 582 | 1.140 |
Why?
|
| Myometrium | 3 | 2022 | 174 | 1.130 |
Why?
|
| Potassium Chloride | 16 | 2013 | 229 | 1.120 |
Why?
|
| Pulmonary Artery | 6 | 2022 | 1927 | 1.110 |
Why?
|
| Venous Insufficiency | 3 | 2024 | 108 | 1.100 |
Why?
|
| Endothelin-1 | 7 | 2013 | 301 | 1.050 |
Why?
|
| Estradiol | 12 | 2013 | 1936 | 1.050 |
Why?
|
| Placental Circulation | 4 | 2021 | 37 | 1.050 |
Why?
|
| Myocytes, Smooth Muscle | 6 | 2022 | 698 | 1.010 |
Why?
|
| NG-Nitroarginine Methyl Ester | 16 | 2015 | 260 | 1.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 4 | 2018 | 558 | 1.000 |
Why?
|
| Thrombospondins | 3 | 2022 | 194 | 0.990 |
Why?
|
| Nitric Oxide Synthase | 10 | 2015 | 908 | 0.990 |
Why?
|
| Adaptation, Physiological | 5 | 2016 | 1301 | 0.990 |
Why?
|
| Signal Transduction | 29 | 2020 | 23415 | 0.970 |
Why?
|
| Vasomotor System | 3 | 2016 | 208 | 0.960 |
Why?
|
| Vasodilator Agents | 14 | 2013 | 989 | 0.900 |
Why?
|
| Angiotensin I | 1 | 2023 | 52 | 0.900 |
Why?
|
| Sodium Chloride, Dietary | 6 | 2011 | 292 | 0.880 |
Why?
|
| Biological Phenomena | 1 | 2023 | 28 | 0.870 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2017 | 151 | 0.850 |
Why?
|
| Enzyme Induction | 3 | 2013 | 452 | 0.810 |
Why?
|
| Nitric Oxide Synthase Type III | 6 | 2013 | 705 | 0.810 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2024 | 145 | 0.780 |
Why?
|
| Menopause | 6 | 2012 | 1646 | 0.770 |
Why?
|
| Sodium, Dietary | 3 | 2015 | 425 | 0.750 |
Why?
|
| Aortic Aneurysm, Abdominal | 3 | 2020 | 1228 | 0.740 |
Why?
|
| Veins | 4 | 2015 | 767 | 0.740 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2021 | 4340 | 0.740 |
Why?
|
| Placentation | 2 | 2020 | 78 | 0.730 |
Why?
|
| Endothelins | 8 | 2014 | 127 | 0.730 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2021 | 91 | 0.720 |
Why?
|
| Receptor, Endothelin A | 3 | 2014 | 55 | 0.670 |
Why?
|
| Receptors, Endothelin | 3 | 2011 | 56 | 0.640 |
Why?
|
| Enzyme Inhibitors | 20 | 2015 | 3700 | 0.630 |
Why?
|
| Receptors, Mineralocorticoid | 3 | 2015 | 163 | 0.620 |
Why?
|
| Arteries | 5 | 2015 | 1121 | 0.600 |
Why?
|
| Acetylcholine | 11 | 2012 | 629 | 0.600 |
Why?
|
| Sodium Chloride | 4 | 2006 | 584 | 0.600 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 1 | 2018 | 57 | 0.590 |
Why?
|
| Epoprostenol | 4 | 2012 | 247 | 0.580 |
Why?
|
| Disease | 3 | 2017 | 670 | 0.570 |
Why?
|
| Muscle Relaxation | 4 | 2012 | 138 | 0.570 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2021 | 1168 | 0.570 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 3 | 2017 | 97 | 0.570 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2017 | 60 | 0.570 |
Why?
|
| Isoenzymes | 9 | 2005 | 1682 | 0.550 |
Why?
|
| Receptor, Angiotensin, Type 2 | 2 | 2023 | 60 | 0.550 |
Why?
|
| Coronary Vasospasm | 5 | 2004 | 81 | 0.530 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2018 | 254 | 0.530 |
Why?
|
| Organ Specificity | 3 | 2017 | 1963 | 0.530 |
Why?
|
| Female | 84 | 2024 | 392458 | 0.520 |
Why?
|
| Calcium Channel Blockers | 7 | 2016 | 694 | 0.520 |
Why?
|
| Enzyme Assays | 1 | 2017 | 104 | 0.520 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2021 | 500 | 0.510 |
Why?
|
| Collagen | 3 | 2022 | 2635 | 0.510 |
Why?
|
| HELLP Syndrome | 1 | 2015 | 40 | 0.510 |
Why?
|
| Vascular Resistance | 6 | 2013 | 932 | 0.500 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 212 | 0.490 |
Why?
|
| Calmodulin-Binding Proteins | 2 | 2015 | 233 | 0.480 |
Why?
|
| Isometric Contraction | 7 | 2013 | 150 | 0.480 |
Why?
|
| Receptor, Angiotensin, Type 1 | 5 | 2023 | 153 | 0.480 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2019 | 10755 | 0.480 |
Why?
|
| Testosterone | 9 | 2023 | 2472 | 0.470 |
Why?
|
| Phytoestrogens | 2 | 2012 | 59 | 0.470 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2017 | 1731 | 0.460 |
Why?
|
| Intracellular Membranes | 3 | 2002 | 387 | 0.460 |
Why?
|
| Blood Circulation | 1 | 2015 | 248 | 0.460 |
Why?
|
| Renal Artery | 3 | 2015 | 351 | 0.460 |
Why?
|
| Sex Characteristics | 6 | 2023 | 2638 | 0.450 |
Why?
|
| Litter Size | 3 | 2021 | 49 | 0.450 |
Why?
|
| Collagen Type I | 1 | 2017 | 616 | 0.450 |
Why?
|
| Extracellular Matrix | 7 | 2020 | 1720 | 0.450 |
Why?
|
| Pancreatic Elastase | 2 | 2004 | 126 | 0.440 |
Why?
|
| Peptide Fragments | 3 | 2023 | 5103 | 0.440 |
Why?
|
| Disease Models, Animal | 12 | 2020 | 18217 | 0.440 |
Why?
|
| Protease Inhibitors | 3 | 2012 | 752 | 0.440 |
Why?
|
| Placental Insufficiency | 2 | 2004 | 50 | 0.440 |
Why?
|
| Mesenteric Veins | 1 | 2013 | 86 | 0.420 |
Why?
|
| Receptors, Epoprostenol | 1 | 2012 | 12 | 0.410 |
Why?
|
| Coronary Vessels | 7 | 2004 | 3111 | 0.410 |
Why?
|
| Plant Preparations | 1 | 2013 | 94 | 0.410 |
Why?
|
| Protein Kinase C-epsilon | 3 | 2007 | 43 | 0.410 |
Why?
|
| Up-Regulation | 5 | 2017 | 4111 | 0.410 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2021 | 3493 | 0.400 |
Why?
|
| Gene Expression Regulation | 4 | 2020 | 11856 | 0.400 |
Why?
|
| Cardiovascular Diseases | 8 | 2017 | 15513 | 0.400 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2015 | 1249 | 0.400 |
Why?
|
| Acidosis, Respiratory | 1 | 2012 | 37 | 0.400 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 36 | 0.390 |
Why?
|
| Electrophysiological Phenomena | 1 | 2014 | 307 | 0.390 |
Why?
|
| Venous Pressure | 2 | 2008 | 55 | 0.390 |
Why?
|
| Escin | 1 | 2011 | 2 | 0.380 |
Why?
|
| RNA Interference | 1 | 2020 | 2816 | 0.380 |
Why?
|
| Blotting, Western | 8 | 2015 | 5033 | 0.380 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2011 | 109 | 0.370 |
Why?
|
| Down-Regulation | 5 | 2020 | 2915 | 0.360 |
Why?
|
| Airway Remodeling | 1 | 2012 | 132 | 0.360 |
Why?
|
| Pressoreceptors | 1 | 2010 | 99 | 0.360 |
Why?
|
| Substrate Specificity | 4 | 2017 | 1768 | 0.350 |
Why?
|
| Dinoprost | 5 | 2003 | 139 | 0.350 |
Why?
|
| Thorax | 1 | 2013 | 555 | 0.350 |
Why?
|
| Oxytocin | 3 | 2022 | 402 | 0.340 |
Why?
|
| Humans | 74 | 2024 | 761098 | 0.340 |
Why?
|
| Aorta, Thoracic | 8 | 2015 | 1096 | 0.340 |
Why?
|
| Cardiovascular System | 2 | 2015 | 836 | 0.320 |
Why?
|
| Renal Circulation | 2 | 2009 | 291 | 0.320 |
Why?
|
| Lower Extremity | 1 | 2017 | 1201 | 0.320 |
Why?
|
| Muscles | 1 | 2014 | 1567 | 0.320 |
Why?
|
| Male | 57 | 2024 | 360675 | 0.320 |
Why?
|
| Proteinuria | 2 | 2022 | 604 | 0.310 |
Why?
|
| Drug Design | 1 | 2014 | 1045 | 0.310 |
Why?
|
| Leukocyte Rolling | 1 | 2008 | 69 | 0.300 |
Why?
|
| Splanchnic Circulation | 1 | 2008 | 119 | 0.300 |
Why?
|
| Membrane Potentials | 6 | 2011 | 1089 | 0.300 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2008 | 131 | 0.300 |
Why?
|
| Developing Countries | 1 | 2020 | 2862 | 0.300 |
Why?
|
| Mesentery | 1 | 2008 | 202 | 0.300 |
Why?
|
| Enzyme Activation | 11 | 2007 | 3577 | 0.280 |
Why?
|
| Potassium Channel Blockers | 3 | 2015 | 161 | 0.280 |
Why?
|
| Abdomen | 1 | 2013 | 1128 | 0.280 |
Why?
|
| Protein Kinase C-alpha | 1 | 2007 | 113 | 0.280 |
Why?
|
| Nitroprusside | 5 | 2012 | 272 | 0.280 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 619 | 0.270 |
Why?
|
| Tissue Distribution | 5 | 2017 | 2262 | 0.270 |
Why?
|
| Cardiovascular Agents | 1 | 2013 | 842 | 0.270 |
Why?
|
| Calcium, Dietary | 1 | 2009 | 529 | 0.270 |
Why?
|
| Culture Techniques | 5 | 2004 | 531 | 0.260 |
Why?
|
| Gamma Rays | 1 | 2007 | 318 | 0.260 |
Why?
|
| Organ Culture Techniques | 2 | 2019 | 793 | 0.260 |
Why?
|
| Microcirculation | 2 | 2008 | 1280 | 0.260 |
Why?
|
| Eclampsia | 1 | 2006 | 56 | 0.260 |
Why?
|
| Nitrites | 4 | 2013 | 156 | 0.250 |
Why?
|
| Interleukin-6 | 3 | 2024 | 3210 | 0.250 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2010 | 528 | 0.250 |
Why?
|
| Calmodulin | 1 | 2006 | 217 | 0.250 |
Why?
|
| Cytokines | 4 | 2022 | 7386 | 0.240 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2006 | 109 | 0.240 |
Why?
|
| Hyperglycemia | 1 | 2013 | 1375 | 0.240 |
Why?
|
| Endothelial Cells | 5 | 2011 | 3550 | 0.240 |
Why?
|
| Rats, Inbred SHR | 5 | 2003 | 186 | 0.240 |
Why?
|
| Estrus | 2 | 2014 | 70 | 0.240 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 1133 | 0.240 |
Why?
|
| Swine | 10 | 2004 | 5909 | 0.230 |
Why?
|
| Hemodynamics | 2 | 2017 | 4164 | 0.230 |
Why?
|
| Kidney | 4 | 2009 | 7034 | 0.230 |
Why?
|
| MicroRNAs | 1 | 2020 | 3758 | 0.230 |
Why?
|
| Diltiazem | 3 | 2016 | 131 | 0.230 |
Why?
|
| Potassium Channels | 1 | 2007 | 537 | 0.230 |
Why?
|
| Cyclins | 1 | 2006 | 594 | 0.220 |
Why?
|
| Placenta Diseases | 1 | 2006 | 199 | 0.220 |
Why?
|
| Dilatation, Pathologic | 3 | 2013 | 527 | 0.220 |
Why?
|
| Calcium Channels | 3 | 2009 | 620 | 0.220 |
Why?
|
| Fetal Growth Retardation | 2 | 2018 | 580 | 0.220 |
Why?
|
| Aging | 3 | 2009 | 8701 | 0.220 |
Why?
|
| Cadherins | 1 | 2008 | 902 | 0.220 |
Why?
|
| Anticoagulants | 1 | 2019 | 4795 | 0.220 |
Why?
|
| Cerebrovascular Circulation | 1 | 2013 | 2725 | 0.210 |
Why?
|
| Osmolar Concentration | 5 | 2012 | 658 | 0.210 |
Why?
|
| Extracellular Space | 2 | 2002 | 563 | 0.210 |
Why?
|
| Cells, Cultured | 8 | 2024 | 18926 | 0.210 |
Why?
|
| Metalloproteases | 1 | 2022 | 61 | 0.200 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2013 | 1554 | 0.200 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 4405 | 0.200 |
Why?
|
| Ferrets | 5 | 1995 | 177 | 0.200 |
Why?
|
| Tissue Culture Techniques | 2 | 2017 | 289 | 0.200 |
Why?
|
| Receptors, Oxytocin | 1 | 2022 | 69 | 0.200 |
Why?
|
| Aldosterone | 3 | 2011 | 869 | 0.190 |
Why?
|
| Guanylate Cyclase | 2 | 2013 | 205 | 0.190 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2024 | 691 | 0.190 |
Why?
|
| RNA, Messenger | 5 | 2022 | 12743 | 0.190 |
Why?
|
| Fura-2 | 5 | 2001 | 107 | 0.190 |
Why?
|
| Monocrotaline | 2 | 2012 | 26 | 0.190 |
Why?
|
| Adrenergic alpha-Agonists | 4 | 2004 | 177 | 0.190 |
Why?
|
| Oligopeptides | 3 | 2014 | 1178 | 0.180 |
Why?
|
| Nitrates | 3 | 2013 | 260 | 0.180 |
Why?
|
| Eicosanoids | 2 | 2002 | 282 | 0.180 |
Why?
|
| Connexins | 1 | 2022 | 352 | 0.180 |
Why?
|
| Receptors, Adrenergic, alpha | 3 | 2010 | 146 | 0.180 |
Why?
|
| Apoptosis | 3 | 2021 | 9478 | 0.180 |
Why?
|
| Antihypertensive Agents | 2 | 2012 | 2019 | 0.180 |
Why?
|
| Maleimides | 2 | 2016 | 112 | 0.180 |
Why?
|
| Thrombophlebitis | 2 | 2013 | 289 | 0.170 |
Why?
|
| Reactive Oxygen Species | 3 | 2016 | 2138 | 0.170 |
Why?
|
| Scleroderma, Localized | 2 | 2013 | 87 | 0.170 |
Why?
|
| Leukocytes | 1 | 2008 | 2024 | 0.170 |
Why?
|
| Muscle Tonus | 3 | 2012 | 82 | 0.170 |
Why?
|
| Regional Blood Flow | 2 | 2019 | 1498 | 0.170 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2002 | 291 | 0.170 |
Why?
|
| Sodium | 2 | 2002 | 1589 | 0.170 |
Why?
|
| Mice, Knockout | 5 | 2015 | 14393 | 0.170 |
Why?
|
| Models, Animal | 4 | 2010 | 2114 | 0.170 |
Why?
|
| Phosphorylation | 5 | 2016 | 8303 | 0.170 |
Why?
|
| Catheter Ablation | 1 | 2013 | 2751 | 0.170 |
Why?
|
| Oxytocics | 1 | 2000 | 67 | 0.170 |
Why?
|
| Aorta, Abdominal | 2 | 2017 | 625 | 0.170 |
Why?
|
| Oxidative Stress | 3 | 2009 | 3114 | 0.160 |
Why?
|
| Collagen Type IV | 1 | 2019 | 125 | 0.160 |
Why?
|
| Spironolactone | 2 | 2015 | 412 | 0.160 |
Why?
|
| Phenols | 2 | 2015 | 517 | 0.160 |
Why?
|
| Hindlimb | 1 | 2021 | 513 | 0.160 |
Why?
|
| Oxadiazoles | 3 | 2004 | 94 | 0.150 |
Why?
|
| Membrane Proteins | 1 | 2015 | 7844 | 0.150 |
Why?
|
| Animals, Newborn | 2 | 2019 | 2666 | 0.150 |
Why?
|
| Trophoblasts | 1 | 2019 | 223 | 0.150 |
Why?
|
| Kidney Diseases | 1 | 2009 | 2092 | 0.150 |
Why?
|
| Immunoblotting | 4 | 2008 | 1644 | 0.150 |
Why?
|
| Cell Cycle | 1 | 2006 | 2926 | 0.150 |
Why?
|
| Risk Factors | 10 | 2020 | 74219 | 0.150 |
Why?
|
| Fertility | 1 | 2022 | 768 | 0.150 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2011 | 361 | 0.150 |
Why?
|
| Lipoproteins, LDL | 1 | 2001 | 643 | 0.150 |
Why?
|
| Receptors, Progesterone | 1 | 2022 | 1129 | 0.150 |
Why?
|
| Gelatinases | 1 | 2017 | 88 | 0.140 |
Why?
|
| Enzyme Activators | 1 | 2017 | 57 | 0.140 |
Why?
|
| Saphenous Vein | 4 | 2024 | 516 | 0.140 |
Why?
|
| Enzyme Precursors | 1 | 2017 | 167 | 0.140 |
Why?
|
| Cysteine | 1 | 2022 | 888 | 0.140 |
Why?
|
| Ion Transport | 3 | 2003 | 320 | 0.140 |
Why?
|
| Rats, Inbred WKY | 4 | 2001 | 150 | 0.140 |
Why?
|
| Hyperhomocysteinemia | 1 | 2017 | 118 | 0.140 |
Why?
|
| Phorbol 12,13-Dibutyrate | 3 | 2001 | 40 | 0.140 |
Why?
|
| rho-Associated Kinases | 2 | 2009 | 281 | 0.130 |
Why?
|
| Amino Acid Motifs | 1 | 2019 | 925 | 0.130 |
Why?
|
| Gestational Age | 2 | 2017 | 3577 | 0.130 |
Why?
|
| Mice | 8 | 2020 | 81324 | 0.130 |
Why?
|
| Quinoxalines | 3 | 2004 | 296 | 0.130 |
Why?
|
| Sex Factors | 6 | 2010 | 10552 | 0.130 |
Why?
|
| Myosin Light Chains | 1 | 2016 | 121 | 0.130 |
Why?
|
| Endopeptidases | 1 | 2020 | 766 | 0.130 |
Why?
|
| Tetraethylammonium | 1 | 2015 | 55 | 0.130 |
Why?
|
| Lung | 2 | 2012 | 9979 | 0.130 |
Why?
|
| Peripheral Arterial Disease | 2 | 2017 | 1274 | 0.130 |
Why?
|
| Dimerization | 1 | 2017 | 888 | 0.130 |
Why?
|
| Birth Weight | 2 | 2019 | 2101 | 0.130 |
Why?
|
| Renin-Angiotensin System | 2 | 2015 | 735 | 0.120 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2017 | 282 | 0.120 |
Why?
|
| Cell Hypoxia | 1 | 2017 | 656 | 0.120 |
Why?
|
| Verapamil | 3 | 2004 | 242 | 0.120 |
Why?
|
| Nitriles | 2 | 2010 | 971 | 0.120 |
Why?
|
| Protein Transport | 3 | 2007 | 1959 | 0.120 |
Why?
|
| Maternal Health Services | 1 | 2020 | 460 | 0.120 |
Why?
|
| Angiogenic Proteins | 1 | 2015 | 101 | 0.120 |
Why?
|
| Viper Venoms | 1 | 2014 | 15 | 0.120 |
Why?
|
| Tetradecanoylphorbol Acetate | 4 | 2004 | 818 | 0.120 |
Why?
|
| Chronic Disease | 3 | 2024 | 9317 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 4565 | 0.110 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 11066 | 0.110 |
Why?
|
| Labor, Obstetric | 1 | 2017 | 323 | 0.110 |
Why?
|
| Carotid Arteries | 2 | 2015 | 941 | 0.110 |
Why?
|
| Heart Injuries | 1 | 2015 | 206 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 1790 | 0.110 |
Why?
|
| Mitogens | 1 | 1993 | 229 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2009 | 475 | 0.110 |
Why?
|
| Hydrostatic Pressure | 1 | 2013 | 98 | 0.100 |
Why?
|
| Coronary Circulation | 1 | 1999 | 1611 | 0.100 |
Why?
|
| Thromboxane-A Synthase | 1 | 2012 | 34 | 0.100 |
Why?
|
| Caffeine | 3 | 2003 | 700 | 0.100 |
Why?
|
| Leg | 1 | 2017 | 1087 | 0.100 |
Why?
|
| Plants, Medicinal | 1 | 2013 | 165 | 0.100 |
Why?
|
| Pyrazoles | 2 | 2015 | 2010 | 0.100 |
Why?
|
| Reference Values | 3 | 2008 | 4922 | 0.100 |
Why?
|
| Protein Isoforms | 2 | 2011 | 1696 | 0.100 |
Why?
|
| Indoles | 2 | 2016 | 1830 | 0.100 |
Why?
|
| Ammonium Chloride | 1 | 2012 | 72 | 0.100 |
Why?
|
| Age Factors | 3 | 2020 | 18385 | 0.100 |
Why?
|
| Prostaglandins I | 1 | 2011 | 13 | 0.100 |
Why?
|
| Potassium | 3 | 1993 | 1309 | 0.100 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2012 | 105 | 0.100 |
Why?
|
| Peptides, Cyclic | 1 | 2014 | 392 | 0.100 |
Why?
|
| Protein Multimerization | 1 | 2017 | 974 | 0.100 |
Why?
|
| Cholinergic Agonists | 1 | 2012 | 75 | 0.100 |
Why?
|
| Fetal Development | 1 | 2017 | 768 | 0.100 |
Why?
|
| Nucleic Acid Conformation | 1 | 2015 | 896 | 0.100 |
Why?
|
| Tyrosine | 2 | 1996 | 1422 | 0.100 |
Why?
|
| Diosmin | 1 | 2011 | 6 | 0.100 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 1 | 2011 | 18 | 0.100 |
Why?
|
| Norepinephrine | 3 | 1990 | 898 | 0.100 |
Why?
|
| Muscle, Smooth | 2 | 1992 | 927 | 0.100 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 318 | 0.090 |
Why?
|
| Echinomycin | 1 | 2010 | 2 | 0.090 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2011 | 42 | 0.090 |
Why?
|
| Myography | 1 | 2012 | 111 | 0.090 |
Why?
|
| Probability | 2 | 2008 | 2478 | 0.090 |
Why?
|
| Naphthalenes | 2 | 2004 | 198 | 0.090 |
Why?
|
| Sapogenins | 1 | 2010 | 2 | 0.090 |
Why?
|
| Dermatitis | 1 | 2013 | 202 | 0.090 |
Why?
|
| Phytotherapy | 1 | 2013 | 296 | 0.090 |
Why?
|
| Ginsenosides | 1 | 2010 | 12 | 0.090 |
Why?
|
| Butadienes | 1 | 2010 | 107 | 0.090 |
Why?
|
| Integrins | 1 | 2015 | 834 | 0.090 |
Why?
|
| Physical Stimulation | 1 | 2012 | 517 | 0.090 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2021 | 1643 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 597 | 0.090 |
Why?
|
| Benzoquinones | 1 | 2010 | 198 | 0.090 |
Why?
|
| Subcellular Fractions | 2 | 2001 | 525 | 0.090 |
Why?
|
| Gene Expression | 2 | 2021 | 7567 | 0.090 |
Why?
|
| Hypertrophy | 1 | 2012 | 558 | 0.090 |
Why?
|
| Receptors, Angiotensin | 1 | 2010 | 140 | 0.090 |
Why?
|
| Progestins | 1 | 2012 | 301 | 0.080 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2012 | 413 | 0.080 |
Why?
|
| Hematologic Diseases | 1 | 2014 | 496 | 0.080 |
Why?
|
| Estrogen Antagonists | 1 | 2010 | 150 | 0.080 |
Why?
|
| Catalytic Domain | 1 | 2012 | 702 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2012 | 10213 | 0.080 |
Why?
|
| Molecular Sequence Data | 3 | 2012 | 17598 | 0.080 |
Why?
|
| Inflammation | 1 | 2009 | 10758 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 1996 | 2426 | 0.080 |
Why?
|
| Renin | 1 | 2011 | 639 | 0.080 |
Why?
|
| Cell Separation | 3 | 2001 | 1718 | 0.080 |
Why?
|
| Lactams, Macrocyclic | 1 | 2010 | 318 | 0.080 |
Why?
|
| Genomic Imprinting | 1 | 2010 | 323 | 0.080 |
Why?
|
| Histone Demethylases | 1 | 2011 | 322 | 0.080 |
Why?
|
| Cytosol | 2 | 2007 | 883 | 0.080 |
Why?
|
| Biopsy | 1 | 2020 | 6781 | 0.080 |
Why?
|
| Orchiectomy | 2 | 2001 | 463 | 0.070 |
Why?
|
| Ovariectomy | 2 | 2001 | 613 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 471 | 0.070 |
Why?
|
| Carbon Dioxide | 1 | 2012 | 1148 | 0.070 |
Why?
|
| Cromakalim | 1 | 2007 | 22 | 0.070 |
Why?
|
| Rabbits | 5 | 2011 | 4749 | 0.070 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2007 | 43 | 0.070 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2007 | 21 | 0.070 |
Why?
|
| Losartan | 1 | 2009 | 263 | 0.070 |
Why?
|
| Phenotype | 2 | 2017 | 16572 | 0.070 |
Why?
|
| Time Factors | 6 | 2010 | 39953 | 0.070 |
Why?
|
| Ethinyl Estradiol | 1 | 2007 | 113 | 0.070 |
Why?
|
| Ankle Brachial Index | 2 | 2017 | 163 | 0.070 |
Why?
|
| Organ Size | 1 | 2012 | 2253 | 0.070 |
Why?
|
| Sympathetic Fibers, Postganglionic | 1 | 2006 | 14 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 2455 | 0.070 |
Why?
|
| Indomethacin | 1 | 2007 | 323 | 0.070 |
Why?
|
| NAD | 1 | 2010 | 611 | 0.070 |
Why?
|
| Protein Kinases | 1 | 1993 | 1607 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2022 | 10421 | 0.070 |
Why?
|
| Cytoskeleton | 2 | 2007 | 1169 | 0.070 |
Why?
|
| Lymphokines | 1 | 2009 | 925 | 0.070 |
Why?
|
| Feedback, Physiological | 1 | 2008 | 475 | 0.070 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2009 | 390 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 431 | 0.060 |
Why?
|
| Synovial Membrane | 1 | 2009 | 532 | 0.060 |
Why?
|
| Prosthesis Design | 1 | 2013 | 2115 | 0.060 |
Why?
|
| Aneurysm | 1 | 2009 | 337 | 0.060 |
Why?
|
| Metformin | 1 | 2013 | 906 | 0.060 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2007 | 276 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 3 | 1995 | 2468 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2013 | 1967 | 0.060 |
Why?
|
| Guinea Pigs | 1 | 2007 | 1309 | 0.060 |
Why?
|
| Piperidines | 1 | 2014 | 1656 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 6507 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 880 | 0.060 |
Why?
|
| Portal Vein | 3 | 1992 | 432 | 0.060 |
Why?
|
| Ligands | 1 | 2012 | 3266 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2015 | 5413 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 4243 | 0.060 |
Why?
|
| Equipment Design | 1 | 2013 | 3509 | 0.060 |
Why?
|
| Water-Electrolyte Balance | 1 | 2006 | 325 | 0.060 |
Why?
|
| Vasculitis | 1 | 2009 | 522 | 0.060 |
Why?
|
| Capillary Permeability | 1 | 2008 | 773 | 0.060 |
Why?
|
| Coronary Restenosis | 1 | 2007 | 396 | 0.060 |
Why?
|
| Heart Valve Prosthesis | 1 | 2013 | 1463 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 15308 | 0.060 |
Why?
|
| Immune System | 1 | 2009 | 792 | 0.060 |
Why?
|
| Atherosclerosis | 2 | 2012 | 3405 | 0.060 |
Why?
|
| Random Allocation | 1 | 2008 | 2393 | 0.060 |
Why?
|
| Intracellular Fluid | 1 | 2003 | 201 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2014 | 1909 | 0.050 |
Why?
|
| Constriction | 1 | 2003 | 168 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 2948 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2024 | 64670 | 0.050 |
Why?
|
| Blood Coagulation | 1 | 2009 | 1156 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 3060 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 6504 | 0.050 |
Why?
|
| Stress, Mechanical | 2 | 2016 | 1674 | 0.050 |
Why?
|
| Calcium Channel Agonists | 1 | 2002 | 26 | 0.050 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2002 | 34 | 0.050 |
Why?
|
| Calcium Radioisotopes | 1 | 2002 | 9 | 0.050 |
Why?
|
| Imidazoles | 1 | 2009 | 1173 | 0.050 |
Why?
|
| Phorbol Esters | 2 | 2001 | 108 | 0.050 |
Why?
|
| Kidney Medulla | 1 | 2002 | 169 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 2270 | 0.050 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2002 | 90 | 0.050 |
Why?
|
| Stimulation, Chemical | 2 | 1999 | 306 | 0.050 |
Why?
|
| Lipid Peroxides | 1 | 2001 | 74 | 0.050 |
Why?
|
| Wound Healing | 1 | 2013 | 2801 | 0.050 |
Why?
|
| Natriuresis | 1 | 2001 | 105 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 14676 | 0.050 |
Why?
|
| China | 2 | 2017 | 2374 | 0.050 |
Why?
|
| Base Sequence | 1 | 2012 | 12404 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2006 | 13404 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 3086 | 0.050 |
Why?
|
| Cell Movement | 1 | 2013 | 5195 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 5662 | 0.040 |
Why?
|
| Hypertension, Renal | 1 | 2001 | 135 | 0.040 |
Why?
|
| Isotonic Solutions | 1 | 2001 | 117 | 0.040 |
Why?
|
| Models, Biological | 1 | 2017 | 9455 | 0.040 |
Why?
|
| Culture Media | 1 | 2002 | 894 | 0.040 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 2 | 1991 | 56 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 2024 | 677 | 0.040 |
Why?
|
| Castration | 1 | 2000 | 150 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2009 | 2413 | 0.040 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2001 | 213 | 0.040 |
Why?
|
| Monocytes | 1 | 2009 | 2570 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2012 | 3812 | 0.040 |
Why?
|
| Methylene Blue | 1 | 2000 | 155 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 1624 | 0.040 |
Why?
|
| Carbazoles | 1 | 2001 | 220 | 0.040 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 1998 | 65 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 2217 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2001 | 339 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 2855 | 0.040 |
Why?
|
| Biological Transport | 2 | 1994 | 2082 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2009 | 2477 | 0.040 |
Why?
|
| Staurosporine | 1 | 1999 | 241 | 0.040 |
Why?
|
| Isoquinolines | 2 | 1991 | 352 | 0.040 |
Why?
|
| Postmenopause | 1 | 2007 | 2511 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2003 | 878 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2004 | 1594 | 0.040 |
Why?
|
| Carcinogens | 1 | 2000 | 452 | 0.040 |
Why?
|
| Diet | 2 | 2008 | 8047 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2001 | 543 | 0.040 |
Why?
|
| Obesity | 1 | 1999 | 12937 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2017 | 22157 | 0.030 |
Why?
|
| Perfusion | 1 | 2002 | 1390 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 2870 | 0.030 |
Why?
|
| Arginine | 1 | 2001 | 921 | 0.030 |
Why?
|
| Body Weight | 1 | 2008 | 4618 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 1240 | 0.030 |
Why?
|
| Pyridines | 1 | 2009 | 2872 | 0.030 |
Why?
|
| Genotype | 1 | 2011 | 12983 | 0.030 |
Why?
|
| Myocardium | 1 | 2009 | 4746 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2003 | 1077 | 0.030 |
Why?
|
| Serotonin | 1 | 2001 | 1043 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2004 | 4014 | 0.030 |
Why?
|
| Vitamin D | 1 | 2009 | 3302 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2024 | 1885 | 0.030 |
Why?
|
| Middle Aged | 5 | 2024 | 220835 | 0.030 |
Why?
|
| Peptides | 1 | 2007 | 4353 | 0.030 |
Why?
|
| Differential Threshold | 1 | 1994 | 80 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 489 | 0.030 |
Why?
|
| Phosphotyrosine | 1 | 1995 | 455 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 1996 | 9001 | 0.030 |
Why?
|
| Mitochondria | 1 | 2007 | 3620 | 0.030 |
Why?
|
| Homocysteine | 1 | 2017 | 637 | 0.030 |
Why?
|
| Hypertonic Solutions | 1 | 1993 | 82 | 0.030 |
Why?
|
| Mammals | 1 | 1998 | 1131 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2001 | 1902 | 0.030 |
Why?
|
| Logistic Models | 2 | 2017 | 13254 | 0.030 |
Why?
|
| Adult | 2 | 2024 | 221083 | 0.020 |
Why?
|
| Sarcolemma | 1 | 1991 | 65 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2012 | 26187 | 0.020 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2011 | 18 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 1991 | 383 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 3419 | 0.020 |
Why?
|
| Aged | 4 | 2024 | 169266 | 0.020 |
Why?
|
| Prevalence | 2 | 2017 | 15717 | 0.020 |
Why?
|
| Microscopy | 1 | 1995 | 904 | 0.020 |
Why?
|
| Piperazines | 2 | 1991 | 2522 | 0.020 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 1987 | 163 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 17889 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2017 | 9648 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 12058 | 0.010 |
Why?
|
| Rats, Inbred Dahl | 1 | 2002 | 34 | 0.010 |
Why?
|
| Ion Channels | 1 | 1987 | 1039 | 0.010 |
Why?
|
| Guanidines | 1 | 2002 | 194 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2011 | 4250 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2002 | 517 | 0.010 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 2 | 1990 | 87 | 0.010 |
Why?
|
| Thionucleotides | 2 | 1990 | 107 | 0.010 |
Why?
|
| Guanosine Triphosphate | 2 | 1990 | 314 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 13630 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1987 | 2802 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2017 | 24013 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2002 | 2181 | 0.010 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 1992 | 100 | 0.010 |
Why?
|
| Heart Rate | 1 | 2002 | 4196 | 0.010 |
Why?
|
| Egtazic Acid | 1 | 1990 | 166 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 1990 | 286 | 0.010 |
Why?
|
| Buffers | 1 | 1989 | 143 | 0.010 |
Why?
|
| Methods | 1 | 1989 | 1063 | 0.000 |
Why?
|
| Cell Division | 1 | 1996 | 4451 | 0.000 |
Why?
|
| Permeability | 1 | 1989 | 721 | 0.000 |
Why?
|
| GTP-Binding Proteins | 1 | 1989 | 946 | 0.000 |
Why?
|